Values as of: 2024-10-21
COMMON STOCK | Medical Devices |
Last Closing
USD 369.14Change
0.00 (0.00)%Market Cap
USD 22.01BVolume
N/AAnalyst Target
N/AVerdict
Verdict
Sonova Holding AG manufactures and sells hearing care solutions for adults and children in the United States, Europe, the Middle East, Africa, and the Asia Pacific. It operates through two segments, Hearing Instruments and Cochlear Implants segments. The Hearing Instruments segments engages in the design, development, manufacture, distribution, and service of hearing instruments and related products, as well as wireless headsets, speech-enhanced hearables, and audiophile headphones under the Phonak, Unitron, Hansaton, and Sennheiser brand names; and audiological care services under the AudioNova, Audium, Audition Santé, Boots Hearingcare, Connect Hearing, Geers, Hansaton, Lapperre, Schoonenberg, and Triton Hearing brands. The Cochlear Implants segment is involved in the design, development, manufacture, distribution, and service of hearing implants and related products under the Advanced Bionics brand. The company sells its products through independent distributors; and provides hearing care services through a network of stores and clinics. The company was formerly known as Phonak Holding AG and changed its name to Sonova Holding AG in August 2007. The company was founded in 1947 and is headquartered in Stäfa, Switzerland.
Company Website : https://www.sonova.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| SEMHF | Siemens Healthineers AG |
N/A |
USD 63.76B |
| SMMNY | Siemens Healthineers AG ADR |
-0.34 (-1.21%) |
USD 63.04B |
| RYLPF | Koninklijke Philips N.V |
+0.09 (+0.27%) |
USD 29.91B |
| SNNUF | Smith & Nephew plc |
N/A |
USD 12.38B |
| WILLF | Demant A/S |
-0.45 (-1.15%) |
USD 8.53B |
| GNGBF | Getinge AB |
+0.01 (+0.02%) |
USD 5.12B |
| AMBBY | Ambu A/S |
-0.17 (-0.92%) |
USD 4.97B |
| AMBFF | Ambu A/S |
N/A |
USD 4.94B |
| GGNDF | GN Store Nord A/S |
N/A |
USD 3.10B |
| GNNDY | GN Store Nord A/S ADR |
N/A |
USD 2.99B |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| EMID:LSE | iShares MSCI Europe Mid C.. | 0.00 % | 0.00 % |
-0.03 (-0.73%) |
N/A |
| EUMD:LSE | iShares MSCI Europe Mid C.. | 0.00 % | 0.00 % |
-0.06 (-0.73%) |
USD 0.27B |
| Market Performance vs. Industry/Classification (Medical Devices) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 13.82% | 67% | D+ | 62% | D | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 13.82% | 67% | D+ | 62% | D | ||
| Trailing 12 Months | |||||||
| Capital Gain | 53.21% | 74% | C | 77% | C+ | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 53.21% | 74% | C | 77% | C+ | ||
| Trailing 5 Years | |||||||
| Capital Gain | 65.99% | 82% | B | 79% | B- | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 65.99% | 82% | B | 79% | B- | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 13.88% | 60% | D- | 58% | F | ||
| Dividend Return | 15.13% | 61% | D- | 57% | F | ||
| Total Return | 1.25% | 70% | C- | 29% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 34.27% | 82% | B | 66% | D+ | ||
| Risk Adjusted Return | 44.16% | 92% | A | 81% | B- | ||
| Market Capitalization | 22.01B | 97% | N/A | 95% | A | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
This stock has shown below median revenue growth in the previous 5 years compared to its sector
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
